Identification of complement C3 as an autoantigen in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Autoimmunity

Background:

• Autoantibodies targeting goblet cells are observed in inflammatory bowel disease (IBD).
• The specific autoantigen responsible for this response has remained unidentified.
• Identifying autoantigens is crucial for understanding IBD pathogenesis.

Purpose of the Study:

• To identify the autoantigen targeted by autoantibodies in patients with IBD.
• To investigate the role of potential autoantigens in gastrointestinal autoimmunity.

Main Methods:

• Screening of an appendiceal cDNA library using sera from IBD patients.
• Immunoprecipitation and Western blot analysis to confirm antigen-antibody interactions.
• Enzyme-linked immunosorbent assay (ELISA) to validate findings with purified C3 protein.

Main Results:

• Complement C3 was identified as a positive clone from the immunoscreening.
• Immunoreactivity to C3 was detected in sera from patients with IBD and primary sclerosing cholangitis.
• No C3 immunoreactivity was observed in sera from healthy individuals, confirming specificity.

Conclusions:

• Complement C3 is identified as a potential autoantigen in inflammatory bowel disease (IBD).
• Complement C3 is also implicated as a potential autoantigen in primary sclerosing cholangitis.
• This finding opens new avenues for diagnostic and therapeutic strategies in IBD and PSC.